ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted KarkĮnergy, banks and agriculture have plenty of value stocks this year but what about healthcare? The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022. Wainwright 24th Annual Global Investment Conference on Septemat 2:30 pm, Eastern Time. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be featured as a presenting company at the H.C. 06, 2022 (GLOBE NEWSWIRE) - ProPhase Labs, Inc. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE) (PRPH) and Concert Pharmaceuticals (CNCE) have performed compared to their sector so far this year. Are Medical Stocks Lagging ProPhase Labs (PRPH) This Year? The table below shows PRPH's key quality metrics over time.īelow are the latest news stories about PROPHASE LABS INC that investors may wish to consider to help them evaluate PRPH as an investment opportunity. NBIX, CEMI, and ENDP are the stocks whose asset turnover ratios are most correlated with PRPH.PRPH's asset turnover comes in at 0.618 - ranking 52nd of 680 Pharmaceutical Products stocks.PRPH has a Quality Grade of F, ranking ahead of 3.86% of graded US stocks.Here are some key insights as we drill into the specifics of these quality attributes. PRPH's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. The table below shows PRPH's growth in key financial areas (numbers in millions of US dollars). PRPH's revenue has moved up $109,684,000 over the prior 70 months. Its 3 year net cashflow from operations growth rate is now at 2747.27%.The 2 year net cashflow from operations growth rate now stands at 843.24%.Its 4 year revenue growth rate is now at -56.2%. PRPH's price/sales ratio has moved down 0.4 over the prior 243 months.īelow are key valuation metrics over time for PRPH.PRPH's price/sales ratio is 1.4 this is 74.55% lower than that of the median Healthcare stock.And to visit PROPHASE LABS INC's official web site, go to PRPH Valuation Summary Stocks that are quantitatively similar to PRPH, based on their financial statements, market capitalization, and price volatility, are ATSG, AAWW, LTHM, DISH, and DLHC.As for revenue growth, note that PRPH's revenue has grown 292.78% over the past 12 months that beats the revenue growth of 96.59% of US companies in our set.Over the past twelve months, PRPH has reported earnings growth of -3,956.37%, putting it ahead of just 0.38% of US stocks in our set.

With a price/earnings ratio of 6.7, PROPHASE LABS INC P/E ratio is greater than that of about just 16.61% of stocks in our set with positive earnings.PRPH's current lowest rank is in the Stability metric (where it is better than 5.98% of US stocks).PRPH's strongest trending metric is Stability it's been moving down over the last 86 days.Sentiment is the dimension where PRPH ranks best there it ranks ahead of 99.32% of US stocks.

Prophase labs stock